Anti-Human IL-17RA (CD217) (Brodalumab) - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Interleukin 17 (IL-17) is a pro-inflammatory cytokine crucial to host defense, tissue repair, pathogenesis of inflammatory disease, and progression of cancer1. IL-17 signaling is also criticalfor protection against fungal and bacterial infection2. There are six pro-inflammatory cytokines(IL-17A-F) produced by Th17 cells, and the IL-17RA receptor is used by IL-17A, IL-17C, IL-17E, and IL-17F to promote signaling and downstream responses3. IL-17RA binds IL-17 withcoreceptor IL-17RC to initiate signaling events1, 2. Blocking the IL-17RA receptor prevents therelease of IL-17-mediated proinflammatory protein kinases and chemokines3. IL-17 and IL-17RA blockade have therefore been explored as immunotherapy for various autoimmunediseases. Brodalumab binds with high affinity to human IL-17RA and blocks signaling of IL-17A, F, andA/F heterodimer via the IL-17RA/RC complex as well as IL-17E signaling via the IL-17RA/RBcomplex 4, 5 4, 5.Brodalumab is approved to treat moderate to severe plaque psoriasis but was found to makeCrohn’s disease worse3. Brodalumab is also known as AMG 827/KHK 48276.

≥ 5.0 mg/ml

IL-17RA is ubiquitously expressed.